Newsletter Tool

Today's Rundown

The top 20 pharma companies by 2021 revenue
Workers at Cedars-Sinai, Stanford Health and Sutter Health eye labor strikes for more pay, safer staffing
New antibiotics still a decade away unless policymakers, investors step up, AMR Action Fund CEO warns
FDA says stroke-spotting AI hasn’t replaced doctors yet, urges providers to stay in the loop
Novartis' global revamp to cost thousands of jobs for simpler structures: report
White House seeks to clamp down on providers' predatory debt collection practices
Aeglea's search for signs of efficacy in phase 3 rare disease data impresses investors, sending stock up 30%
AACR: AbbVie's navitoclax goes after tough blood cancer, not yet reaching overall survival benchmark
Myovant, Pfizer's expansion bid for Myfembree hits a snag at the FDA
Roche wins appeal to overturn $137M lab-testing patent infringement penalty
Ansa Biotechnologies ties up $68M for DNA synthesis platform
Insurtech unicorn Sidecar Health launches new group employer plan in Ohio
Akili’s video game treatment for depression improves cognitive symptoms: study

Featured Story

The top 20 pharma companies by 2021 revenue

By Kevin Dunleavy

2021 was all about recovery from the COVID-19 pandemic. Several companies that quickly developed products to combat the coronavirus reaped huge profits, while others benefited simply from a return to more normalized business operations. Here's how the year shook out for the top 20 drugmakers by global revenues.

Workers at Cedars-Sinai, Stanford Health and Sutter Health eye labor strikes for more pay, safer staffing

By Dave Muoio

Cedars-Sinai, Stanford Health Care and Sutter Health have each been the recipient of new activity within the past few days. Nurses and healthcare workers across the California provider organizations are all calling for higher wages and safer workplace policies.

New antibiotics still a decade away unless policymakers, investors step up, AMR Action Fund CEO warns

By Gabrielle Masson

Despite the growing threat posed by drug-resistant bacteria, new antibiotics may not reach the market for another decade, according to the head of a $1 billion fund tasked with seeking out solutions.

FDA says stroke-spotting AI hasn’t replaced doctors yet, urges providers to stay in the loop

By Conor Hale

According to the agency, some healthcare providers may not be using these AI aids as intended when evaluating potential large-vessel occlusions.

Novartis' global revamp to cost thousands of jobs for simpler structures: report

By Angus Liu

Novartis is undertaking a huge restructuring to simplify its organization, and thousands of the employees will reportedly feel the pain.

White House seeks to clamp down on providers' predatory debt collection practices

By Robert King

HHS is calling for more than 2,000 providers to offer key information on their billing practices, with the information to be used to inform grantmaking decisions.

Aeglea's search for signs of efficacy in phase 3 rare disease data impresses investors, sending stock up 30%

By Nick Paul Taylor

Aeglea BioTherapeutics’ bid to rehabilitate the battered reputation of its rare disease drug pegzilarginase has made early progress. Investors responded favorably to the presentation of additional phase 3 data, sending the stock up 21% in light of evidence the enzyme may act on clinical outcomes.

AACR: AbbVie's navitoclax goes after tough blood cancer, not yet reaching overall survival benchmark

By Annalee Armstrong

Myelofibrosis is the cancer that keeps going and going—and AbbVie hopes new data from the phase 2 med navitoclax can make the case for stopping the rare and difficult-to-treat disease in its tracks.

Myovant, Pfizer's expansion bid for Myfembree hits a snag at the FDA

By Kevin Dunleavy

Myovant and Pfizer’s application for Myfembree to treat endometriosis has hit a snag. In a letter to the companies, the FDA has identified deficiencies that “preclude discussion of labeling and/or post-marketing requirements and commitments at this time.” The combo drug was up for a May 6 decision.

PM Tracker

Featured Story

The top 20 pharma companies by 2021 revenue

Top Stories

Workers at Cedars-Sinai, Stanford Health and Sutter Health eye labor strikes for more pay, safer staffing

New antibiotics still a decade away unless policymakers, investors step up, AMR Action Fund CEO warns

FDA says stroke-spotting AI hasn’t replaced doctors yet, urges providers to stay in the loop

Novartis' global revamp to cost thousands of jobs for simpler structures: report

White House seeks to clamp down on providers' predatory debt collection practices

Aeglea's search for signs of efficacy in phase 3 rare disease data impresses investors, sending stock up 30%

AACR: AbbVie's navitoclax goes after tough blood cancer, not yet reaching overall survival benchmark

Myovant, Pfizer's expansion bid for Myfembree hits a snag at the FDA

Roche wins appeal to overturn $137M lab-testing patent infringement penalty

Ansa Biotechnologies ties up $68M for DNA synthesis platform

Insurtech unicorn Sidecar Health launches new group employer plan in Ohio

Akili’s video game treatment for depression improves cognitive symptoms: study